Cargando…

Late toxicity after post-prostatectomy intensity modulated radiation therapy: Evaluating normal-tissue sparing guidelines

PURPOSE: Dose-volume histogram (DVH) toxicity relationships are poorly defined in men who receive radiation after radical prostatectomy (RP). We evaluated Radiation Therapy Oncology Group (RTOG) study 0534 and institutional intact normal-tissue sparing guidelines, as well as dose to bladder trigone,...

Descripción completa

Detalles Bibliográficos
Autores principales: Akthar, Adil S., Wong, Anthony C., Parekh, Akash D., Hubert, Greg, Son, Christina H., Pelizzari, Charles A., Liauw, Stanley L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6128032/
https://www.ncbi.nlm.nih.gov/pubmed/30202803
http://dx.doi.org/10.1016/j.adro.2018.04.009
_version_ 1783353582759706624
author Akthar, Adil S.
Wong, Anthony C.
Parekh, Akash D.
Hubert, Greg
Son, Christina H.
Pelizzari, Charles A.
Liauw, Stanley L.
author_facet Akthar, Adil S.
Wong, Anthony C.
Parekh, Akash D.
Hubert, Greg
Son, Christina H.
Pelizzari, Charles A.
Liauw, Stanley L.
author_sort Akthar, Adil S.
collection PubMed
description PURPOSE: Dose-volume histogram (DVH) toxicity relationships are poorly defined in men who receive radiation after radical prostatectomy (RP). We evaluated Radiation Therapy Oncology Group (RTOG) study 0534 and institutional intact normal-tissue sparing guidelines, as well as dose to bladder trigone, for ability to minimize late toxicity. METHODS AND MATERIALS: 164 men received intensity modulated radiation therapy (RT) to a median prostate bed dose of 66.6 Gy at a median of 22 months after RP. 46% of men were prescribed androgen deprivation therapy and pelvic lymph node irradiation to a median dose of 50.4 Gy. DVH relationships for the rectum, bladder, trigone, and bladder excluding the clinical target volume (bladder-CTV) were analyzed against the Common Terminology Criteria for Adverse Events late grade 2 + (G2+) gastrointestinal (GI) and genitourinary (GU) toxicity by log-rank test. RTOG 0534 (rectum V65, 40 Gy ≤35, 55%, and bladder-CTV V65, 40 ≤50, 70%) and intact prostate RT institutional guidelines (rectum V70, 65, 40 ≤20, 40, 80% and bladder V70, 65, 40 ≤30, 60, 80%, respectively) guidelines were evaluated. RESULTS: With a median follow-up time of of 33 months, the 4-year freedom from G2 + GI and GU toxicity were both 91%. G2 + GI (n = 12) and GU (n = 15) toxicity included 4% diarrhea (n = 6), 4% hemorrhage (n = 6), 1% proctitis (n = 1), and 4% urinary frequency (n = 7), 1% obstructive (n = 2), 2% cystitis (n = 3), and 3% incontinence (n = 5), respectively. RTOG 0534 rectum and bladder goals were not achieved in 65% and 41% of cases, while the institutional intact prostate goals were not achieved in 21% and 25% of cases, respectively. Neither dose to the bladder trigone nor any of the proposed normal tissue goals were associated with late toxicity (P > .1). In the univariate analysis, age, pelvic RT, RT dose, anticoagulation use, androgen deprivation therapy, time from RP to RT, and tobacco history were not associated with toxicity. CONCLUSIONS: More than 90% of men were free from late G2 + toxicity 4 years after post-RP intensity modulated RT. No tested parameters were associated with late toxicity. In the absence of established normal-tissue DVH guidelines in the postoperative setting, the use of intact guidelines is reasonable.
format Online
Article
Text
id pubmed-6128032
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-61280322018-09-10 Late toxicity after post-prostatectomy intensity modulated radiation therapy: Evaluating normal-tissue sparing guidelines Akthar, Adil S. Wong, Anthony C. Parekh, Akash D. Hubert, Greg Son, Christina H. Pelizzari, Charles A. Liauw, Stanley L. Adv Radiat Oncol Genitourinary Cancer PURPOSE: Dose-volume histogram (DVH) toxicity relationships are poorly defined in men who receive radiation after radical prostatectomy (RP). We evaluated Radiation Therapy Oncology Group (RTOG) study 0534 and institutional intact normal-tissue sparing guidelines, as well as dose to bladder trigone, for ability to minimize late toxicity. METHODS AND MATERIALS: 164 men received intensity modulated radiation therapy (RT) to a median prostate bed dose of 66.6 Gy at a median of 22 months after RP. 46% of men were prescribed androgen deprivation therapy and pelvic lymph node irradiation to a median dose of 50.4 Gy. DVH relationships for the rectum, bladder, trigone, and bladder excluding the clinical target volume (bladder-CTV) were analyzed against the Common Terminology Criteria for Adverse Events late grade 2 + (G2+) gastrointestinal (GI) and genitourinary (GU) toxicity by log-rank test. RTOG 0534 (rectum V65, 40 Gy ≤35, 55%, and bladder-CTV V65, 40 ≤50, 70%) and intact prostate RT institutional guidelines (rectum V70, 65, 40 ≤20, 40, 80% and bladder V70, 65, 40 ≤30, 60, 80%, respectively) guidelines were evaluated. RESULTS: With a median follow-up time of of 33 months, the 4-year freedom from G2 + GI and GU toxicity were both 91%. G2 + GI (n = 12) and GU (n = 15) toxicity included 4% diarrhea (n = 6), 4% hemorrhage (n = 6), 1% proctitis (n = 1), and 4% urinary frequency (n = 7), 1% obstructive (n = 2), 2% cystitis (n = 3), and 3% incontinence (n = 5), respectively. RTOG 0534 rectum and bladder goals were not achieved in 65% and 41% of cases, while the institutional intact prostate goals were not achieved in 21% and 25% of cases, respectively. Neither dose to the bladder trigone nor any of the proposed normal tissue goals were associated with late toxicity (P > .1). In the univariate analysis, age, pelvic RT, RT dose, anticoagulation use, androgen deprivation therapy, time from RP to RT, and tobacco history were not associated with toxicity. CONCLUSIONS: More than 90% of men were free from late G2 + toxicity 4 years after post-RP intensity modulated RT. No tested parameters were associated with late toxicity. In the absence of established normal-tissue DVH guidelines in the postoperative setting, the use of intact guidelines is reasonable. Elsevier 2018-05-08 /pmc/articles/PMC6128032/ /pubmed/30202803 http://dx.doi.org/10.1016/j.adro.2018.04.009 Text en © 2018 The Authors http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Genitourinary Cancer
Akthar, Adil S.
Wong, Anthony C.
Parekh, Akash D.
Hubert, Greg
Son, Christina H.
Pelizzari, Charles A.
Liauw, Stanley L.
Late toxicity after post-prostatectomy intensity modulated radiation therapy: Evaluating normal-tissue sparing guidelines
title Late toxicity after post-prostatectomy intensity modulated radiation therapy: Evaluating normal-tissue sparing guidelines
title_full Late toxicity after post-prostatectomy intensity modulated radiation therapy: Evaluating normal-tissue sparing guidelines
title_fullStr Late toxicity after post-prostatectomy intensity modulated radiation therapy: Evaluating normal-tissue sparing guidelines
title_full_unstemmed Late toxicity after post-prostatectomy intensity modulated radiation therapy: Evaluating normal-tissue sparing guidelines
title_short Late toxicity after post-prostatectomy intensity modulated radiation therapy: Evaluating normal-tissue sparing guidelines
title_sort late toxicity after post-prostatectomy intensity modulated radiation therapy: evaluating normal-tissue sparing guidelines
topic Genitourinary Cancer
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6128032/
https://www.ncbi.nlm.nih.gov/pubmed/30202803
http://dx.doi.org/10.1016/j.adro.2018.04.009
work_keys_str_mv AT aktharadils latetoxicityafterpostprostatectomyintensitymodulatedradiationtherapyevaluatingnormaltissuesparingguidelines
AT wonganthonyc latetoxicityafterpostprostatectomyintensitymodulatedradiationtherapyevaluatingnormaltissuesparingguidelines
AT parekhakashd latetoxicityafterpostprostatectomyintensitymodulatedradiationtherapyevaluatingnormaltissuesparingguidelines
AT hubertgreg latetoxicityafterpostprostatectomyintensitymodulatedradiationtherapyevaluatingnormaltissuesparingguidelines
AT sonchristinah latetoxicityafterpostprostatectomyintensitymodulatedradiationtherapyevaluatingnormaltissuesparingguidelines
AT pelizzaricharlesa latetoxicityafterpostprostatectomyintensitymodulatedradiationtherapyevaluatingnormaltissuesparingguidelines
AT liauwstanleyl latetoxicityafterpostprostatectomyintensitymodulatedradiationtherapyevaluatingnormaltissuesparingguidelines